



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Andrew W. Shyjan, et al.

Serial No.: 09/374,554

Filed: August 13, 1999

For: *METHODS OF COMPOSITIONS FOR THE IDENTIFICATION AND ASSESSMENT OF CANCER THERAPIES*

Attorney Docket No.: MRI-005CP2

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, D.C. 20231

Group Art Unit: 1643

Examiner: Not yet assigned

REQUEST FOR CORRECTION OF FILING RECEIPT

Dear Sir:

The Filing Receipt in the above-identified application contains some errors. Please correct the spelling of the word "Methods" where indicated.

METHODS AND COMPOSITIONS FOR THE IDENTIFICATION AND ASSESSMENT OF CANCER THERAPIES

The Filing Receipt also lists an incorrect docket number. The correct information should read as follows:

Docket Number: MRI-005CP2

Applicants request that the Filing Receipt be corrected and reissued. *A copy of the Filing Receipt with the changes noted thereon is submitted herewith.*

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Office of Initial Patent Examination, Customer Service Center, Washington, D.C. 20231 on:

September 5, 2000


Date

DeAnn F. Smith

Reg. No. 36,683

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



DeAnn F. Smith
Registration No. 36,683
Attorney for Applicants

FILING RECEIPT



OC00000005288819

UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAddress: ASSISTANT SECRETARY AND
COMMISSIONER OF PATENT AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/374,554	08/13/1999	1643	1718	MRF-005	-	40	9

959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109



MRI-005CP2

Date Mailed: 08/02/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)


ANDREW W. SHYLAN, NAHANT, MA;
CHRISTOPHE VAN HUFFEL, Brussels, BELGIUM;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/322,864 05/28/1999
AND CLAIMS BENEFIT OF 09/233,611 01/19/1999
AND CLAIMS BENEFIT OF 60/079,399 03/26/1998
AND CLAIMS BENEFIT OF 60/071,940 01/20/1998
WHICH CLAIMS BENEFIT OF 60/105,968 10/28/1998

Foreign Applications

If Required, Foreign Filing License Granted 08/31/1999



Title

Methods
METHOD AND COMPOSITIONS FOR THE IDENTIFICATION AND ASSESSMENT OF CANCER
THERAPIES

Preliminary Class

436

Data entry by : DAY, DOSHIE

Team : OIPE

Date: 08/02/2000

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
 Office of Initial Patent Examination
 Customer Service Center
 Washington, DC 20231